Company news
Q32 Bio Inc. news in 2020
Q32 Bio Inc.'s news releases, calls and decks from 2020, newest first.
Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights
November 8, 2020
Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.
November 8, 2020
Homology Medicines Announces Presentation of Positive Data from the Dose-Escalation Phase of the pheNIX Gene Therapy Trial for Adults with PKU
November 5, 2020
Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU
November 4, 2020
Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome
October 21, 2020
Homology Medicines to Participate in Upcoming Conferences
September 17, 2020
Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update
August 9, 2020
Homology Medicines Appoints Jeff Poulton to the Board of Directors
July 20, 2020
Homology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU Program
May 25, 2020
Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Gene Editing Programs and Commercial Manufacturing Platform at the American Society of Gene & Cell Therapy Annual Meeting
May 11, 2020
Homology Medicines Reports First Quarter 2020 Financial Results and Recent Highlights
May 6, 2020
Homology Medicines Announces Presentations at Upcoming American Society for Gene & Cell Therapy Annual Meeting
April 28, 2020
Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model
March 15, 2020